VANCOUVER, British Columbia, Sept. 24, 2018 (GLOBE NEWSWIRE) — Novoheart (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company, announced today that it has appointed Bernard Fermini, Ph.D.as Chief Research & Development Officer.
Dr. Fermini has been a leading figure and expert in cardiac safety pharmacology for over two decades. Having received a Ph.D in Biophysics from the University of Sherbrooke (Canada), he joined the Montreal Heart Institute where he led a research team focusing on electrophysiology of the atrial chambers of the heart. He moved to Merck before joining Pfizer for what became a 17-year tenure. At Pfizer, he held positions of increasing responsibilities including Co-chair of the Global Safety Pharmacology Department. He began collaborating with the Novoheart team while at Pfizer, and will be bringing his substantial expertise in safety pharmacology to complement Novoheart’s scientific team’s strengths in stem cell and tissue engineering.
Since 2013, Dr. Fermini has been the Co-chairman of the Ion Channel Working Group of the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative headed by the US Food and Drug Administration (FDA). As Co-chairman, he oversees the research into identifying next-generation screening methods for effective detection of drug-induced cardiac arrhythmias before clinical trials. Dr. Fermini is also a Board Member on the CiPA Steering Committee and committee member of the Safety Pharmacology Society, as well as an active member of Health and Environmental Sciences Institute (HESI) Cardiac Safety Committee and the Society of Toxicology. As a key opinion leader, Dr. Fermini will lead Novoheart’s industrial expansion in drug discovery and development, leveraging his extensive experience and networks in the pharma industry.
“Human stem cell-derived cardiac assays are the future for drug screening, as witnessed by the rapid developments in this area and the interest shown by pharma as well as regulatory agencies such as the FDA,” said Dr. Fermini. “With Novoheart’s impressive bioengineered heart tissue technologies, I see immense potential in revolutionizing preclinical testing; I look forward to being a part of the Novoheart team to campaign for an industry-wide adoption of these next-generation, cutting-edge assays.”
“We are very excited by the appointment of Bernard, with whom we have had a wonderful collaboration at Pfizer,” said Dr. Ronald Li, Co-founder & CEO of Novoheart. “With his well-recognized stature in the safety pharmacology community, the addition of Dr. Fermini to our team further validates our revolutionary technology to prospective clients who are seeking to implement it into their drug discovery and screening processes, and his endorsement will send out a powerful message to the industry. We look forward to having Bernard lead our development in the areas of drug discovery as a recognized industry expert.”
About Novoheart:
Novoheart is a global stem cell biotechnology company pioneering an array of next-generation human heart tissue prototypes. It is the first company in the world to have engineered miniature living human heart pumps that can revolutionize drug discovery, helping to save time and money for developing new therapeutics. Also known as ‘human heart-in-a-jar’, Novoheart’s bio-artificial human heart constructs are created using state-of-the-art and proprietary stem cell and bioengineering approaches and are utilized by drug developers for accurate preclinical testing as to the effectiveness and safety of new drugs, maximizing the successes in drug discovery whilst minimizing costs and harm caused to patients.
For further information, please contact:
Ronald Li, CEO
info@novoheart.com
Babak Pedram, Investor Relations
Virtus Advisory Group
Tel: 416-995-8651
bpedram@virtusadvisory.com
For media enquiries or interviews, please contact:
Josh Stanbury, Media Relations
Tel. 416-628-7441
media@novoheart.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. All statements, other than statements of historical fact, included herein including, without limitation; statements about the Company’s future plans, its goals and expectations, and the potential applications of its MyHeartTM platform are forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks identified in the management discussion and analysis section of Novoheart Holdings Inc.’s interim and most recent annual financial statement or other reports and filings with the TSX Venture Exchange and applicable Canadian securities regulators. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and the respective companies undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements.
